Carlsquare advised DENA A/S, a Danish family office focused on healthcare investments, on the sale of BiopSafe ApS to MedCap AB, a listed Swedish investment company specialising in niche healthcare and medical technology businesses.
BiopSafe ApS is a Denmark-based medical device company specialising in closed prefilled biopsy containers and, until the transaction, a portfolio company of DENA A/S, a Danish family office committed to responsible ownership. BiopSafe’s patented closed system enables safe, formalin-free biopsy handling, protecting medical personnel from the harmful effects of formaldehyde, addressing a critical occupational health challenge for pathology and clinical staff globally. The company is showing a strong profitable growth and has a commercial presence across several European markets.
MedCap AB (publ) is a Stockholm-based listed investment company dedicated to acquiring and developing profitable, niche businesses within healthcare and medical technology. Operating primarily in specialised segments of the Nordic healthcare market, MedCap brings together a portfolio of focused companies under dedicated business areas.
The acquisition brings together a commercially proven, innovation-driven medical device company and a focused healthcare investor with deep sector expertise.
”BiopSafe has an innovative product and has established a leading position in its niche on several European markets. The company makes a nice addition to the business area Medtech and we look forward to continuing the development together with the team.” – Anders Dahlberg, CEO MedCap.
Carlsquare acted as the exclusive financial advisor to DENA A/S on this transaction.
